RxDoctor Payments Data

Victor Anazia, DO

Internal Medicine · McComb, MSNPI 1245232792

Payments from drug & device makers

$716in general payments, 2019–2025

Across 35 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$287
  • AstraZeneca$157
  • AbbVie$90
  • Otsuka America Pharmaceutical, Inc.$40
  • Cvrx, Inc.$24
  • Boehringer Ingelheim$23
  • plus $95 from 6 others

What the payments were for

  • Food & beverage$716100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$716 in reported general payments places this provider in the 55th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$165,066
Medicare patients
291
Services billed
2,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol203$102,497
EliquisApixaban138$77,474
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$54,676
LinzessLinaclotide84$53,559
JanuviaSitagliptin Phosphate74$50,986
MounjaroTirzepatide23$31,681
OzempicSemaglutide30$27,324
EntrestoSacubitril/Valsartan34$27,031
XareltoRivaroxaban66$25,605
TradjentaLinagliptin29$18,597
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,931
MyrbetriqMirabegron104$12,160
JardianceEmpagliflozin13$10,747
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl62$10,548
JanumetSitagliptin Phos/Metformin Hcl12$9,379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$157$123,563260 claims
MerckJanuvia, Janumet$13$60,36586 claims
GSKTrelegy Ellipta$21$54,67663 claims
AbbVieLinzess$90$53,55984 claims
Boehringer IngelheimTradjenta, Jardiance$23$29,34342 claims
NovartisEntresto$287$27,03134 claims
Sanofi-aventis U.S. LLCLantus$16$5,86143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in McComb

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →